Mary Elizabeth M. Tessier, MD
- Gastroenterology, Hepatology and Nutrition
Assistant Professor of Pediatrics, Baylor College of Medicine
Phone:
832-822-3131
Fax:
832-825-4131
Languages: English
Office locations:
Texas Medical Center
6701 Fannin Street
Houston, TX 77030
Get to know Mary Elizabeth M. Tessier, MD
Dr. Tessier is a pediatric gastroenterologist and hepatologist with a special interest in pediatric liver diseases. Her research centers on the interplay of the gut microbiome and outcomes in pediatric liver diseases, particularly biliary atresia. She is currently leading a multicenter study examining the effects of the microbiome in biliary atresia and cholestatic liver diseases of infancy.
Dr. Tessier sees a wide variety of pediatric liver diseases and has a special interest in primary sclerosing cholangitis. These patients also often have inflammatory bowel disease and she works collaboratively with her colleagues who specialize in IBD to care for these patients.
Clinical Interests
Cholestatic liver diseases, primary sclerosing cholangitis (PSC), progressive familial intrahepatic cholestasis (PFIC), liver transplantation, general GI
Education
,
,
,
Organizations
,
,
,
* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.
Research interests
Microbiome in pediatric cholestatic liver disease, primary sclerosing cholangitis, human breast milk and outcomes in liver diseases of infancy
Tessier MEM, Cavallo L, Yeh J, Harpavat S, Hoffman KL, Petrosino JF, Shneider BL. The Fecal Microbiome in Infants With Biliary Atresia Associates With Bile Flow After Kasai Portoenterostomy. J Pediatr Gastroenterol Nutr. 2020 Jun;70(6):789-795. doi: 10.1097/MPG.0000000000002686. PMID: 32443032.
Tessier MEM, Shneider BL. 60 Days in Biliary Atresia: A Historical Dogma Challenged. Clin Liver Dis (Hoboken). 2020 Mar 2;15(Suppl 1):S3-S7. doi: 10.1002/cld.843. PMID: 32140208; PMCID: PMC7050960.
Tessier MEM, Shneider BL, Brandt ML, Cerminara DN, Harpavat S. A phase 2 trial of N-Acetylcysteine in Biliary atresia after Kasai portoenterostomy. Contemp Clin Trials Commun. 2019 May 2;15:100370. doi: 10.1016/j.conctc.2019.100370. PMID: 31193715; PMCID: PMC6542754.
Martinez M, Perito ER, Valentino P, Mack CL, Aumar M, Broderick A, Draijer LG, Fagundes EDT, Furuya KN, Gupta N, Horslen S, Jonas MM, Kamath BM, Kerkar N, Kim KM, Kolho KL, Koot BGP, Laborda TJ, Lee CK, Loomes KM, Miloh T, Mogul D, Mohammed S, Ovchinsky N, Rao G, Ricciuto A, Rodrigues Ferreira A, Schwarz KB, Smolka V, Tanaka A, Tessier MEM, Venkat VL, Vitola BE, Woynarowski M, Zerofsky M, Deneau MR. Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study. Hepatology. 2021 Oct;74(4):2047-2057. doi: 10.1002/hep.31911. Epub 2021 Sep 9. PMID: 34008252; PMCID: PMC8530456.
Britto SL, Hoffman KL, Tessier ME, Petrosino J, Miloh T, Kellermayer R. Microbiome Responses to Vancomycin Treatment in a Child With Primary Sclerosing Cholangitis and Ulcerative Colitis. ACG Case Rep J. 2021 May 11;8(5):e00577. doi: 10.14309/crj.0000000000000577. PMID: 33997090; PMCID: PMC8116036.
Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, Dalgic B, D'Antiga L, Durmaz Ö, Fischler B, Gonzalès E, Grammatikopoulos T, Gupte G, Hardikar W, Houwen RHJ, Kamath BM, Karpen SJ, Kjems L, Lacaille F, Lachaux A, Lainka E, Mack CL, Mattsson JP, McKiernan P, Özen H, Rajwal SR, Roquelaure B, Shagrani M, Shteyer E, Soufi N, Sturm E, Tessier ME, Verkade HJ, Horn P. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):830-842. doi: 10.1016/S2468-1253(22)00093-0. Epub 2022 Jul 1. PMID: 35780807.
Tam A, AlDhaheri NS, Mysore K, Tessier ME, Goss J, Fernandez LA, D'Alessandro AM, Schwoerer JS, Rice GM, Elsea SH, Scaglia F. Improved clinical outcome following liver transplant in patients with ethylmalonic encephalopathy. Am J Med Genet A. 2019 Jun;179(6):1015-1019. doi: 10.1002/ajmg.a.61104. Epub 2019 Mar 12. PMID: 30864297; PMCID: PMC9873405.